Burcon Nutrascience (BU) AI Stock Analysis

• Market Cap: C$22.20M
• Dividend Yield: N/A
• Average Volume (3M): 6.58K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.04
• Revenue Growth: 190.07%
• EPS Growth: -2.88%
• Country: CA
• Employees: 25
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): -0.28
• Shares Outstanding: 12,688,076
• 10 Day Avg. Volume: 9,144
• 30 Day Avg. Volume: 6,578
• PEG Ratio: >-0.01
• Price to Book (P/B): 2.14
• Price to Sales (P/S): 38.96
• P/FCF Ratio: -2.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$2.00 ▲(14.29% Upside)

Burcon Nutrascience's overall stock score is primarily impacted by its weak financial performance and technical indicators, which suggest ongoing challenges. However, the positive sentiment from the earnings call provides some optimism for future growth, albeit with significant risks.

Positive Factors

Revenue Growth

The company's projected revenue growth and positive cash flow by 2026 indicate expanding market reach and operational improvements, supporting long-term business sustainability.

Successful Production Integration

Successful production integration of proprietary technology enhances operational efficiency and product availability, strengthening Burcon's competitive position in the plant-based protein market.

Multiyear Production Agreement

The multiyear agreement ensures a reliable revenue stream and operational stability, supporting Burcon's long-term growth and market expansion efforts.

Negative Factors

High Leverage

High leverage increases financial risk, potentially limiting Burcon's ability to invest in growth opportunities and impacting its long-term financial stability.

Negative Cash Flows

Negative cash flows indicate challenges in generating sufficient cash to support operations and growth, posing risks to Burcon's financial health and sustainability.

Negative Profitability

Ongoing negative profitability reflects operational challenges and limits Burcon's ability to reinvest in the business, affecting long-term growth prospects.

Burcon Nutrascience Business Overview & Revenue Model

Company Description

Burcon NutraScience Corporation, together with its subsidiaries, develops plant proteins and ingredients for use in the food and beverage industries in Canada. The company's products include Peazazz, a pea protein for use in dairy alternatives, ready-to-drink beverages, dry blended beverages, bars, baked goods, and meat substitute products; and Peazac and Peazac 850, a pea protein for plant-based meat alternative products, ready-to-mix powders, ready-to-mix beverages, dairy alternatives, and nutrition bars, as well as other applications requiring the most neutral flavor and moderate viscosity. It provides Puratein, a canola protein isolate for use in meat alternatives, such as burgers, sausages, and nutrition bars; Supertein, a canola protein that is a light-colored powder for use in non-dairy frozen desserts, egg alternative, plant-based marshmallows and ready-to-mix beverages, whipped toppings, and plant-based bars; and Nutratein, a canola protein comprising a mixture of globulin and albumin proteins for use in meat and egg alternatives, and other plant-based functional foods. In addition, the company offers Nutratein-PS and Nutratein-TZ, a blend of Peazac pea protein; and CLARISOY, a soy protein for use in sports nutrition beverages, citrus-based drinks, fruit-flavored beverages, lemonades, powdered beverage mixes, and other foods and nutritional products. Further, it provides MeritPro, a nutritional protein blend, including allergen-free, gluten-free, non-dairy, non-GMO, and vegan. The company was formerly known as Burcon Capital Corp. and changed its name to Burcon NutraScience Corporation in October 1999. The company was incorporated in 1998 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Burcon Nutrascience generates revenue through several key streams, including the licensing of its proprietary protein extraction and purification technologies to food manufacturers, which allows them to produce their own plant-based protein products. Additionally, the company sells its protein ingredients directly to food and beverage companies for inclusion in their products. Significant partnerships with major food industry players enhance Burcon's market reach and credibility, contributing to its earnings. The company also explores joint ventures and collaborations that leverage its technology and product offerings in the rapidly expanding plant-based market, providing further avenues for revenue generation.

Burcon Nutrascience Financial Statement Overview

Summary

Burcon Nutrascience is facing significant financial challenges, with negative profitability and high leverage. Despite some revenue growth, the negative cash flows and high debt-to-equity ratio indicate potential liquidity problems and financial instability.

Income Statement

Burcon Nutrascience has shown a modest revenue growth rate of 12.65% in the latest year, which is a positive sign. However, the company is struggling with negative margins across the board, including a significant net profit margin of -2167.1% and negative EBIT and EBITDA margins. These figures indicate ongoing operational challenges and a lack of profitability, which are concerning for the company's financial health.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio, indicating significant leverage, which could pose financial risks. The return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is relatively low, suggesting limited financial stability. Overall, the balance sheet highlights potential risks due to high leverage and low profitability.

Cash Flow

The cash flow statement shows negative operating and free cash flows, with a declining free cash flow growth rate of -9.44%. The operating cash flow to net income ratio is negative, indicating cash flow challenges. These factors suggest that the company is facing difficulties in generating sufficient cash to support its operations and growth.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	486.97K	381.40K	184.36K	363.91K	171.47K	258.65K
Gross Profit	-2.33M	-870.76K	184.36K	363.91K	171.47K	-527.31K
EBITDA	-8.15M	-7.43M	-6.23M	-18.90M	-9.92M	-4.73M
Net Income	-9.87M	-8.26M	-7.45M	-25.36M	-10.26M	-617.49K
Balance Sheet
Total Assets	26.96M	30.66M	12.91M	9.90M	29.35M	37.72M
Cash, Cash Equivalents and Short-Term Investments	4.23M	7.28M	4.20M	1.46M	7.00M	13.97M
Total Debt	22.27M	22.40M	6.67M	5.17M	73.14K	33.70K
Total Liabilities	23.36M	23.71M	7.76M	5.76M	1.10M	1.45M
Stockholders Equity	3.60M	6.94M	5.15M	4.14M	28.25M	36.27M
Cash Flow
Free Cash Flow	-6.62M	-5.82M	-5.90M	-6.38M	-7.18M	-5.91M
Operating Cash Flow	-6.34M	-5.51M	-5.78M	-6.02M	-5.91M	-3.03M
Investing Cash Flow	-1.62M	-1.66M	-39.49K	-4.43M	-1.23M	-2.72M
Financing Cash Flow	10.21M	10.23M	8.56M	4.90M	174.08K	4.70M

Burcon Nutrascience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BU, the sentiment is Negative. The current price of 1.75 is below the 20-day moving average (MA) of 1.97, below the 50-day MA of 2.17, and below the 200-day MA of 2.29, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 35.73 is Neutral, neither overbought nor oversold. The STOCH value of 19.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BU.

Burcon Nutrascience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
BABY	45 Neutral	$7.86M	―	-517.87%	―	-25.08%	65.57%
BU	42 Neutral	C$22.20M	-1.69	-1208.82%	―	190.07%	-2.88%
NPRA	37 Underperform	$14.71M	―	―	―	69.12%	43.02%
PNGA	27 Underperform	C$6.06M	-2.93	-86.40%	―	-49.04%	15.60%
ISTK	25 Underperform	C$252.65M	-114.23	―	―	30.02%	35.29%

Burcon Nutrascience Corporate Events

Burcon NutraScience Reports Strong Q2 Growth

Burcon NutraScience Corporation is a global technology leader specializing in the innovation of plant-based proteins for the food and beverage industry, known for its extensive patent portfolio and commitment to sustainability.

Burcon NutraScience Secures $4 Million in Convertible Debentures to Fuel Growth

Burcon NutraScience Corporation has announced a non-brokered private placement of convertible debentures totaling up to $4 million, with insiders committing to at least $2 million. This financing aims to provide capital flexibility to support Burcon’s growth as it experiences increasing customer demand. The company also entered into a loan agreement for $700,000 to further bolster its financial position. The proceeds from these financial activities will be used to enhance production capabilities, plan for future infrastructure investments, and repay short-term loans, positioning Burcon for accelerated growth and strengthening its market presence.

The most recent analyst rating on (TSE:BU) stock is a Hold with a C$2.50 price target. To see the full list of analyst forecasts on Burcon Nutrascience stock, see the TSE:BU Stock Forecast page.

Burcon NutraScience to Discuss Q2 Financial Results Amid Growing Protein Sales

Burcon NutraScience announced it will hold a conference call on November 12, 2025, to discuss its fiscal 2026 second-quarter financial results. The company is experiencing increased momentum in protein sales as customers transition to commercial purchase orders, reaffirming its 2025 revenue target of $1-3 million. This growing demand is expected to drive revenue acceleration and margin expansion into 2026, highlighting Burcon’s strengthening position in the plant-based protein industry.

The most recent analyst rating on (TSE:BU) stock is a Hold with a C$2.50 price target. To see the full list of analyst forecasts on Burcon Nutrascience stock, see the TSE:BU Stock Forecast page.

Burcon’s Plant-Based Proteins Excel in Cheese Study

Burcon NutraScience Corporation announced that a study by the University of Guelph demonstrated their Peazazz®C pea protein and Solatein™ sunflower protein significantly outperform a leading competitor’s pea protein in plant-based cheese applications. This achievement marks a significant advancement in plant-based cheese production, offering dairy-like melt and stretch properties, and opens new commercial opportunities in the growing dairy-alternative market.

The most recent analyst rating on (TSE:BU) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Burcon Nutrascience stock, see the TSE:BU Stock Forecast page.

Burcon NutraScience Achieves First Commercial Sales of High-Purity Canola Protein

Burcon NutraScience Corporation has announced its first commercial sales of Puratein®C, a high-purity canola protein isolate with over 90% protein content. This milestone is a significant step in Burcon’s strategy to establish recurring revenue and expand its market reach across high-growth product categories. Puratein C, derived from non-GMO, North American-grown canola seeds, is designed to meet the increasing demand for clean-label, nutritionally complete plant proteins. Its versatility makes it suitable for a wide range of food and beverage applications, reinforcing Burcon’s commitment to delivering sustainable protein solutions.

Burcon NutraScience Launches Commercial Production of High-Purity Canola Protein

Burcon NutraScience Corporation has achieved a significant milestone with the first commercial production of Puratein®C, a high-purity canola protein isolate, at its Galesburg facility. This development marks a crucial step in Burcon’s strategy to expand its plant protein portfolio and scale revenue, addressing the increasing global demand for sustainable protein solutions. Puratein®C, derived from non-GMO North American-grown canola seeds, boasts over 90% protein content and a complete amino acid profile, making it ideal for a variety of food and beverage applications. This advancement not only demonstrates Burcon’s capability to scale its innovations but also positions the company to create new revenue streams and enhance its market opportunities.

Burcon NutraScience Prepares for Annual Shareholder Meeting with Key Warrant Amendments

Burcon NutraScience Corporation announced details of its upcoming annual shareholder meeting, which will be held virtually on September 17, 2025. The company is on track to meet its 2025/2026 milestones, with over 150 active customer projects nearing final evaluation, indicating a strong potential for recurring revenue and rapid scaling. A key agenda item for the meeting is the proposal to amend the exercise price of outstanding warrants to $3.50 per share, which requires shareholder approval. This amendment is seen as beneficial for the company and its shareholders, potentially impacting Burcon’s financial strategies and shareholder value.

Burcon NutraScience: Optimism in Earnings Call

The recent earnings call for Burcon NutraScience Corporation was marked by an optimistic tone, underscoring significant advancements in production capabilities, customer engagement, and strategic agreements. Despite some concerns regarding onetime start-up costs, the overall sentiment was positive, with a strong focus on execution and future growth potential.